SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001714899-22-000014
Filing Date
2022-01-10
Accepted
2022-01-10 09:06:06
Documents
14
Period of Report
2022-01-10
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20220110.htm   iXBRL 8-K 40283
2 EX-99.1 ex991pressrelease1102022.htm EX-99.1 53787
6 denali_txlogox02.jpg GRAPHIC 680367
  Complete submission text file 0001714899-22-000014.txt   1172119

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20220110.xsd EX-101.SCH 1932
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20220110_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20220110_pre.xml EX-101.PRE 12528
8 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20220110_htm.xml XML 10900
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 22519972
SIC: 2836 Biological Products, (No Diagnostic Substances)